A new objective for Pfizer Inc. The American company plans to sell this year for 33.5 billion dollars of vaccines developed with the German BioNTech.
That's far more than the $ 26 billion the group said it was banking on in May, and even more than the $ 15 billion estimated in February.
This new forecast is based on contracts signed for 2.1 billion doses to be delivered across the globe.
"The speed and efficiency of our efforts with BioNTech to help vaccinate the world against Covid-19 is unprecedented, with now more than a billion doses delivered globally," responded the CEO of the group, Albert Bourla, quoted in the press release for the second quarter.
Read also Covid-19: half of the French now fully vaccinated, the incentives are multiplying
Sales that could further increase with a 3rd dose
With its sales on the rise, Pfizer has logically raised its forecast for annual sales and profits.
The laboratory now anticipates for the whole of 2021 a turnover of between 78 billion and 80 billion dollars.
Its sales of anti-Covid vaccines have already earned it $ 11.3 billion in the first six months of the year.
Sales could grow further, as Pfizer / BioNTech recommends a third dose of its vaccine to make it more effective against the Delta variant.
"New studies show that a third dose has neutralizing effects against the Delta variant more than five times higher in young people and more than eleven times in older people after two doses," said the company on Wednesday.
The alliance had announced in early July to plan an authorization request for a third dose of its vaccine, in the United States and in Europe.
